Robert M Post

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4429032/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.9	1,079
2	Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Research, 1997, 73, 159-171.	3.3	944
3	Axis I Psychiatric Comorbidity and Its Relationship to Historical Illness Variables in 288 Patients With Bipolar Disorder. American Journal of Psychiatry, 2001, 158, 420-426.	7.2	611
4	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	7.2	579
5	Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. Biological Psychiatry, 2000, 48, 1133-1141.	1.3	528
6	Kindling as a Model for Alcohol Withdrawal Syndromes. British Journal of Psychiatry, 1978, 133, 1-14.	2.8	446
7	The Stanley Foundation Bipolar Treatment Outcome Network. Journal of Affective Disorders, 2001, 67, 45-59.	4.1	436
8	Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. Neuroscience and Biobehavioral Reviews, 2008, 32, 675-692.	6.1	416
9	The Increasing Use of Polypharmacotherapy for Refractory Mood Disorders. Journal of Clinical Psychiatry, 2000, 61, 9-15.	2.2	415
10	A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders. Journal of Clinical Psychopharmacology, 2000, 20, 607-614.	1.4	385
11	Risk of Switch in Mood Polarity to Hypomania or Mania in Patients With Bipolar Depression During Acute and Continuation Trials of Venlafaxine, Sertraline, and Bupropion as Adjuncts to Mood Stabilizers. American Journal of Psychiatry, 2006, 163, 232-239.	7.2	379
12	Early physical and sexual abuse associated with an adverse course of bipolar illness. Biological Psychiatry, 2002, 51, 288-297.	1.3	350
13	Conditioning and Sensitisation in the Longitudinal Course of Affective Illness. British Journal of Psychiatry, 1986, 149, 191-201.	2.8	346
14	The longitudinal course of recurrent affective illness: Life chart data from research patients at the NIMH. Acta Psychiatrica Scandinavica, 1985, 71, 1-33.	4.5	344
15	Morbidity in 258 Bipolar Outpatients Followed for 1 Year With Daily Prospective Ratings on the NIMH Life Chart Method. Journal of Clinical Psychiatry, 2003, 64, 680-690.	2.2	335
16	Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder ¹ . Bipolar Disorders, 2007, 9, 531-535.	1.9	317
17	Frequency dependence of antidepressant response to left prefrontal repetitive transcranial magnetic stimulation (rTMS) as a function of baseline cerebral glucose metabolism. Biological Psychiatry, 1999, 46, 1603-1613.	1.3	305
18	Factors Associated With Suicide Attempts in 648 Patients With Bipolar Disorder in the Stanley Foundation Bipolar Network. Journal of Clinical Psychiatry, 2003, 64, 506-515.	2.2	294

#	Article	IF	CITATIONS
19	Early-Onset Bipolar Disorder and Treatment Delay Are Risk Factors for Poor Outcome in Adulthood. Journal of Clinical Psychiatry, 2010, 71, 864-872.	2.2	282
20	Correlates of Overweight and Obesity in 644 Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2002, 63, 207-213.	2.2	281
21	Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biological Psychiatry, 2001, 49, 97-109.	1.3	275
22	Comparative Prophylactic Efficacy of Lithium, Carbamazepine, and the Combination in Bipolar Disorder. Journal of Clinical Psychiatry, 1997, 58, 470-478.	2.2	270
23	Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biological Psychiatry, 2002, 51, 237-252.	1.3	267
24	Impact of Antidepressant Discontinuation After Acute Bipolar Depression Remission on Rates of Depressive Relapse at 1-Year Follow-Up. American Journal of Psychiatry, 2003, 160, 1252-1262.	7.2	265
25	Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neuroscience and Biobehavioral Reviews, 2007, 31, 858-873.	6.1	265
26	Role of BDNF in bipolar and unipolar disorder: Clinical and theoretical implications. Journal of Psychiatric Research, 2007, 41, 979-990.	3.1	259
27	Prefrontal cortex dysfunction in clinical depression. Depression, 1994, 2, 59-72.	0.6	250
28	Effects of Stress on Neurotrophic Factor Expression in the Rat Brain. Annals of the New York Academy of Sciences, 1995, 771, 234-239.	3.8	228
29	A Placebo-Controlled Evaluation of Adjunctive Modafinil in the Treatment of Bipolar Depression. American Journal of Psychiatry, 2007, 164, 1242-1249.	7.2	224
30	Double-Blind, Randomized, Placebo-Controlled Trials of Ethyl-Eicosapentanoate in the Treatment of Bipolar Depression and Rapid Cycling Bipolar Disorder. Biological Psychiatry, 2006, 60, 1020-1022.	1.3	219
31	The Poor Prognosis of Childhood-Onset Bipolar Disorder. Journal of Pediatrics, 2007, 150, 485-490.	1.8	218
32	Open-label adjunctive topiramate in the treatment of bipolar disorders. Biological Psychiatry, 2000, 47, 1025-1033.	1.3	203
33	Sensitization and kindling phenomena in mood, anxiety, and obsessive–compulsive disorders: the role of serotonergic mechanisms in illness progression. Biological Psychiatry, 1998, 44, 193-206.	1.3	198
34	Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biological Psychiatry, 2003, 53, 906-913.	1.3	191
35	Gender Differences in Prevalence, Risk, and Clinical Correlates of Alcoholism Comorbidity in Bipolar Disorder. American Journal of Psychiatry, 2003, 160, 883-889.	7.2	187
36	Comparison of Rapid-Cycling and Non-Rapid-Cycling Bipolar Disorder Based on Prospective Mood Ratings in 539 Outpatients. American Journal of Psychiatry, 2005, 162, 1273-1280.	7.2	184

#	Article	IF	CITATIONS
37	Subsyndromal Depressive Symptoms Are Associated With Functional Impairment in Patients With Bipolar Disorder. Journal of Clinical Psychiatry, 2006, 67, 1551-1560.	2.2	176
38	Mixed Hypomania in 908 Patients With Bipolar Disorder Evaluated Prospectively in the Stanley Foundation Bipolar Treatment Network. Archives of General Psychiatry, 2005, 62, 1089.	12.3	175
39	Ultra-Rapid and Ultradian Cycling in Bipolar Affective Illness. British Journal of Psychiatry, 1996, 168, 314-323.	2.8	164
40	The Stanley Foundation Bipolar Treatment Outcome Network. Journal of Affective Disorders, 2001, 67, 33-44.	4.1	162
41	Correlates of Treatment-Emergent Mania Associated With Antidepressant Treatment in Bipolar Depression. American Journal of Psychiatry, 2009, 166, 164-172.	7.2	161
42	Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry, 2017, 16, 236-244.	10.4	160
43	Cerebrospinal Fluid Immunoreactive Cortieotropin-Releasing Hormone and Adrenocorticotropin Secretion in Cushing's Disease and Major Depression: Potential Clinical Implications. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 260-271.	3.6	154
44	Dysphoric Mania. Archives of General Psychiatry, 1989, 46, 353.	12.3	153
45	Maternal deprivation increases cell death in the infant rat brain. Developmental Brain Research, 2002, 133, 1-11.	1.7	150
46	Rapid and Non-Rapid Cycling Bipolar Disorder. Journal of Clinical Psychiatry, 2003, 64, 1483-1494.	2.2	145
47	Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation for Acute Treatment of Medication-Resistant Depression. American Journal of Psychiatry, 2011, 168, 356-364.	7.2	141
48	Lower Switch Rate in Depressed Patients With Bipolar II Than Bipolar I Disorder Treated Adjunctively With Second-Generation Antidepressants. American Journal of Psychiatry, 2006, 163, 313-315.	7.2	140
49	Relationship between prior course of illness and neuropsychological functioning in patients with bipolar disorder. Journal of Affective Disorders, 1999, 56, 67-73.	4.1	132
50	Correlates of 1-Year Prospective Outcome in Bipolar Disorder: Results From the Stanley Foundation Bipolar Network. American Journal of Psychiatry, 2004, 161, 1447-1454.	7.2	131
51	Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Research, 1993, 49, 257-272.	3.3	129
52	An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disorders, 2003, 5, 310-319.	1.9	128
53	A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disorders, 2003, 5, 396-406.	1.9	128
54	Neurobiological correlates of illness progression in the recurrent affective disorders. Journal of Psychiatric Research, 2012, 46, 561-573.	3.1	124

#	Article	IF	CITATIONS
55	Age, sex and laterality effects on cerebral glucose metabolism in healthy adults. Psychiatry Research - Neuroimaging, 2002, 114, 23-37.	1.8	122
56	Course of bipolar illness after history of childhood trauma. Lancet, The, 2006, 367, 1040-1042.	13.7	121
57	Alterations in mRNA of enkephalin, dynorphin and thyrotropin releasing hormone during amygdala kindling: an in situ hybridization study. Molecular Brain Research, 1992, 15, 247-255.	2.3	111
58	Bidirectional Synaptic Plasticity in the Rat Basolateral Amygdala: Characterization of an Activity-Dependent Switch Sensitive to the Presynaptic Metabotropic Glutamate Receptor Antagonist 2S-α-Ethylglutamic Acid. Journal of Neuroscience, 1998, 18, 1662-1670.	3.6	110
59	Mouse Brain c-fos mRNA Distribution Following a Single Electroconvulsive Shock. Journal of Neurochemistry, 1989, 52, 1954-1957.	3.9	109
60	Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disorders, 2005, 7, 246-259.	1.9	106
61	Progressive behavioral changes during chronic lidocaine administration: Relationship to kindling. Life Sciences, 1975, 17, 943-950.	4.3	103
62	Bipolar disorder and substance misuse: pathological and therapeutic implications of their comorbidity and cross-sensitisation. British Journal of Psychiatry, 2013, 202, 172-176.	2.8	103
63	Complexity of Pharmacologic Treatment Required for Sustained Improvement in Outpatients With Bipolar Disorder. Journal of Clinical Psychiatry, 2010, 71, 1176-1186.	2.2	103
64	Regional expression of c-fos mRNA in rat brain during the evolution of amygdala kindled seizures. Molecular Brain Research, 1991, 11, 55-64.	2.3	100
65	A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Molecular Neurobiology, 1996, 13, 33-60.	4.0	98
66	Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disorders, 2001, 3, 259-265.	1.9	97
67	Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biological Psychiatry, 2002, 51, 253-260.	1.3	97
68	The Stanley Foundation Bipolar Network. British Journal of Psychiatry, 2001, 178, s169-s176.	2.8	96
69	Olanzapine in treatment-resistant bipolar disorder. Journal of Affective Disorders, 1998, 49, 119-122.	4.1	95
70	Incidence of childhood-onset bipolar illness in the USA and Europe. British Journal of Psychiatry, 2008, 192, 150-151.	2.8	95
71	Life Charting of Affective Disorders. CNS Spectrums, 1998, 3, 21-37.	1.2	86
72	Cognitive impairment in school-aged children with early trauma. Comprehensive Psychiatry, 2012, 53, 758-764.	3.1	86

#	Article	IF	CITATIONS
73	Nimodipine Monotherapy and Carbamazepine Augmentation in Patients With Refractory Recurrent Affective Illness. Journal of Clinical Psychopharmacology, 1998, 18, 404-413.	1.4	86
74	Emergent properties of neural systems: How focal molecular neurobiological alterations can affect behavior. Development and Psychopathology, 1997, 9, 907-929.	2.3	85
75	Mechanisms of Illness Progression in the Recurrent Affective Disorders. Neurotoxicity Research, 2010, 18, 256-271.	2.7	83
76	Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophrenia Research, 2002, 58, 21-30.	2.0	77
77	The New News about Lithium: An Underutilized Treatment in the United States. Neuropsychopharmacology, 2018, 43, 1174-1179.	5.4	76
78	Increased Neural Cell Adhesion Molecule in the CSF of Patients with Mood Disorder. Journal of Neurochemistry, 2002, 66, 1532-1538.	3.9	75
79	Cocaine-Induced Behavioral Sensitization and Kindling: Implications for the Emergence of Psychopathology and Seizures. Annals of the New York Academy of Sciences, 1988, 537, 292-308.	3.8	73
80	Contingent tolerance to the anticonvulsant effects of carbamazepine: Relationship to loss of endogenous adaptive mechanisms. Brain Research Reviews, 1995, 20, 305-325.	9.0	72
81	An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder. Bipolar Disorders, 2019, 21, 720-740.	1.9	71
82	Beyond Lithium in the Treatment of Bipolar Illness. Neuropsychopharmacology, 1998, 19, 206-219.	5.4	70
83	Endogenous biochemical abnormalities in affective illness: Therapeutic versus pathogenic. Biological Psychiatry, 1992, 32, 469-484.	1.3	66
84	Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: Confounding effects of tolerance and implications for therapeutics. Biological Psychiatry, 1997, 41, 264-272.	1.3	66
85	Role of childhood adversity in the development of medical co-morbidities associated with bipolar disorder. Journal of Affective Disorders, 2013, 147, 288-294.	4.1	66
86	Lamotrigine for the treatment of bipolar disorder: a clinical case series. Journal of Affective Disorders, 1999, 53, 95-98.	4.1	65
87	A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disorders, 2007, 9, 426-434.	1.9	65
88	Impact of Antidepressant Continuation After Acute Positive or Partial Treatment Response for Bipolar Depression. Journal of Clinical Psychiatry, 2009, 70, 450-457.	2.2	65
89	Open-Label Adjunctive Zonisamide in the Treatment of Bipolar Disorders. Journal of Clinical Psychiatry, 2005, 66, 617-624.	2.2	65
90	Carbamazepine Prophylaxis in Refractory Affective. Journal of Clinical Psychopharmacology, 1990, 10, 318???327.	1.4	64

#	Article	IF	CITATIONS
91	Verbal abuse, like physical and sexual abuse, in childhood is associated with an earlier onset and more difficult course of bipolar disorder. Bipolar Disorders, 2015, 17, 323-330.	1.9	64
92	Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disorders, 2002, 4, 283-289.	1.9	62
93	Chronic Carbamazepine Treatment Increases Brain Adenosine Receptors. Epilepsia, 1985, 26, 493-498.	5.1	59
94	Metabolism and excretion of mood stabilizers and new anticonvulsants. Cellular and Molecular Neurobiology, 1999, 19, 511-532.	3.3	59
95	Plasma and CSF Gaba in Affective Illness. British Journal of Psychiatry, 1982, 141, 483-487.	2.8	58
96	Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disorders, 1999, 1, 61-65.	1.9	57
97	Epigenetic basis of sensitization to stress, affective episodes, and stimulants: implications for illness progression and prevention. Bipolar Disorders, 2016, 18, 315-324.	1.9	57
98	Recurrent affective disorder: Roots in developmental neurobiology and illness progression based on changes in gene expression. Development and Psychopathology, 1994, 6, 781-813.	2.3	56
99	Analysis of the hippocampal GABAA receptor system in kindled rats by autoradiographic and in situ hybridization techniques: contingent tolerance to carbamazepine. Molecular Brain Research, 1994, 26, 309-319.	2.3	55
100	The Health Care Crisis of Childhood-Onset Bipolar Illness. Journal of Clinical Psychiatry, 2006, 67, 115-125.	2.2	55
101	Do the epilepsies, pain syndromes, and affective disorders share common kindling-like mechanisms?. Epilepsy Research, 2002, 50, 203-219.	1.6	54
102	Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany. International Clinical Psychopharmacology, 2011, 26, 96-106.	1.7	54
103	Preliminary Observations on the Effectiveness of Levetiracetam in the Open Adjunctive Treatment of Refractory Bipolar Disorder. Journal of Clinical Psychiatry, 2005, 66, 370-374.	2.2	53
104	Mixed Depression in Bipolar Disorder: Prevalence Rate and Clinical Correlates During Naturalistic Follow-Up in the Stanley Bipolar Network. American Journal of Psychiatry, 2016, 173, 1015-1023.	7.2	52
105	Developmental psychobiology of cyclic affective illness: Implications for early therapeutic intervention. Development and Psychopathology, 1996, 8, 273-305.	2.3	51
106	Development and Reversal of Contingent Inefficacy and Tolerance to the Anticonvulsant Effects of Carbamazepine. Epilepsia, 1991, 32, 140-145.	5.1	50
107	Open-label aripiprazole in the treatment of acute bipolar depression: A prospective pilot trial. Journal of Affective Disorders, 2007, 101, 275-281.	4.1	50
108	Utility of the daily prospective National Institute of Mental Health Life-Chart Method (NIMH-LCM-p) ratings in clinical trials of bipolar disorder. Depression and Anxiety, 2002, 15, 1-9.	4.1	48

#	Article	IF	CITATIONS
109	More childhood onset bipolar disorder in the United States than Canada or Europe: Implications for treatment and prevention. Neuroscience and Biobehavioral Reviews, 2017, 74, 204-213.	6.1	48
110	More stressors prior to and during the course of bipolar illness in patients from the United States compared with the Netherlands and Germany. Psychiatry Research, 2013, 210, 880-886.	3.3	47
111	Alcoholism and anxiety in bipolar illness: Differential lifetime anxiety comorbidity in bipolar I women with and without alcoholism. Journal of Affective Disorders, 2007, 101, 211-217.	4.1	46
112	Approaches to the Evaluation and Treatment of Rapid-Cycling Affective Illness. British Journal of Psychiatry, 1984, 145, 543-550.	2.8	44
113	Mood Effects of Prefrontal Repetitive High-Frequency TMS in Healthy Volunteers. CNS Spectrums, 1997, 2, 53-68.	1.2	42
114	Differential abnormalities of functional connectivity of the amygdala and hippocampus in unipolar and bipolar affective disorders. Journal of Affective Disorders, 2014, 168, 243-253.	4.1	42
115	Emerging trends in the treatment of rapid cycling bipolar disorder: a selected review. Bipolar Disorders, 2000, 2, 305-315.	1.9	41
116	Age of onset of bipolar disorder: Combined effect of childhood adversity and familial loading of psychiatric disorders. Journal of Psychiatric Research, 2016, 81, 63-70.	3.1	41
117	Unique design issues in clinical trials of patients with bipolar affective disorder. Journal of Psychiatric Research, 2003, 37, 61-73.	3.1	40
118	The Stanley Foundation Bipolar Network. British Journal of Psychiatry, 2001, 178, s177-s183.	2.8	39
119	Antidepressant Efficacy of High and Low Frequency rTMS at 110% of Motor Threshold versus Sham Stimulation over Left Prefrontal Cortex. Brain Stimulation, 2014, 7, 36-41.	1.6	38
120	Paradigm Shift: Preliminary Clinical Categorization of Ultrahigh Risk for Childhood Bipolar Disorder to Facilitate Studies on Prevention. Journal of Clinical Psychiatry, 2013, 74, 167-169.	2.2	37
121	Effects of carbamazepine on cerebrospinal fluid somatostatin. Psychopharmacology, 1985, 85, 210-213.	3.1	36
122	Treatment of Rapid-Cycling Bipolar Disorder. CNS Spectrums, 2004, 9, 1-4.	1.2	36
123	Stress, Conditioning, and the Temporal Aspects of Affective Disorders. Annals of the New York Academy of Sciences, 1995, 771, 677-696.	3.8	35
124	Earliest symptoms discriminating juvenileâ€onset bipolar illness from ADHD. Bipolar Disorders, 2009, 11, 441-451.	1.9	35
125	Relationship of Prior Antidepressant Exposure to Long-Term Prospective Outcome in Bipolar I Disorder Outpatients. Journal of Clinical Psychiatry, 2012, 73, 924-930.	2.2	33
126	Contingent tolerance to carbamazepine: alterations in TRH mRNA and TRH receptor binding in limbic structures. Brain Research, 1994, 651, 252-260.	2.2	32

#	Article	IF	CITATIONS
127	Tolerance to the Anticonvulsant Effects of Lamotrigine on Amygdala Kindled Seizures: Cross-Tolerance to Carbamazepine But Not Valproate or Diazepam. Experimental Neurology, 2000, 162, 278-289.	4.1	32
128	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disorders, 2021, 23, 767-788.	1.9	32
129	Drug-Induced Switching in Bipolar Disorder. CNS Drugs, 1997, 8, 352-365.	5.9	31
130	Interregional cerebral metabolic associativity during a continuous performance task (Part II) : Differential alterations in bipolar and unipolar disorders. Psychiatry Research - Neuroimaging, 2008, 164, 30-47.	1.8	31
131	Alternative approaches to refractory depression in bipolar illness. Depression and Anxiety, 1997, 5, 175-189.	4.1	30
132	Caveats in the use of the Kindling Model of Affective Disorders. Toxicology and Industrial Health, 1994, 10, 421-447.	1.4	30
133	Effects of the 5-HT3 Antagonist, Ondansetron, on the Behavioral and Physiological Effects of Pentagastrin in Patients with Panic Disorder and Social Phobia. Neuropsychopharmacology, 1997, 17, 360-369.	5.4	29
134	Treatment of Bipolar Depression. Psychiatric Clinics of North America, 2016, 39, 11-33.	1.3	29
135	Treatment of Mood Disorders with Antiepileptic Medications: Clinical and Theoretical Implications. Epilepsia, 1983, 24, S97-108.	5.1	28
136	Multigenerational Positive Family History of Psychiatric Disorders Is Associated With a Poor Prognosis in Bipolar Disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 2015, 27, 304-310.	1.8	28
137	Neurobiology of Bipolar Illness: Implications for Future Study and Therapeutics. Annals of Clinical Psychiatry, 2003, 15, 85-94.	0.6	27
138	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. Bipolar Disorders, 2021, 23, 659-678.	1.9	27
139	Lack of Beneficial Effects of L-Baclofen in Affective Disorder. International Clinical Psychopharmacology, 1991, 6, 197-208.	1.7	26
140	Contingent tolerance to carbamazepine: A peripheral-type benzodiazepine mechanism. European Journal of Pharmacology, 1991, 193, 159-163.	3.5	25
141	Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. Comprehensive Psychiatry, 2016, 66, 146-156.	3.1	25
142	Unidirectional Cross-tolerance from Levetiracetam to Carbamazepine in Amygdala-kindled Seizures. Epilepsia, 2003, 44, 1487-1493.	5.1	24
143	Convergences in Course of Illness and Treatments of the Epilepsies and Recurrent Affective Disorders. Clinical EEG and Neuroscience, 2004, 35, 14-24.	1.7	24
144	Acquired lithium resistance revisited: Discontinuation-induced refractoriness versus tolerance. Journal of Affective Disorders, 2012, 140, 6-13.	4.1	24

#	Article	IF	CITATIONS
145	Re-evaluating carbamazepine prophylaxis in bipolar disorder. British Journal of Psychiatry, 1997, 170, 202-204.	2.8	23
146	Preventing the Malignant Transformation of Bipolar Disorder. JAMA - Journal of the American Medical Association, 2018, 319, 1197.	7.4	23
147	Testing a clinical staging model for bipolar disorder using longitudinal life chart data. Bipolar Disorders, 2019, 21, 228-234.	1.9	23
148	Premenstrual Syndromes: Past and Future Research Strategies. Canadian Journal of Psychiatry, 1985, 30, 469-473.	1.9	22
149	Adenosine Antagonist Properties of Carbamazepine. Epilepsia, 1987, 28, 387-394.	5.1	21
150	Colocalization of TRH mRNA and Fos-like Immunoreactivity in Limbic Structures Following Amygdala Kindling. Molecular and Cellular Neurosciences, 1993, 4, 335-342.	2.2	20
151	Low frequency daily left prefrontal rTMS improves mood in bipolar depression: a placebo-controlled case report. Human Psychopharmacology, 1998, 13, 271-275.	1.5	20
152	Saving time and money: a validation of the self ratings on the prospective NIMH life-chart method (NIMH-LCM). BMC Psychiatry, 2014, 14, 130.	2.6	20
153	Association of brainâ€derived neurotrophic factor (<i><scp>BDNF</scp></i>) Val66Met polymorphism with earlyâ€onset bipolar disorder. Bipolar Disorders, 2015, 17, 645-652.	1.9	20
154	Neuroendocrine Effects of Carbamazepine in Patients with Affective Illness. Epilepsia, 1986, 27, 156-160.	5.1	19
155	Corticotropin-Releasing Hormone: Potentiation of Cocaine-Kindled Seizures and Lethality. Epilepsia, 1992, 33, 248-254.	5.1	19
156	Acute and prophylactic effects of anticonvulsants in bipolar depression. Clinical Neuroscience Research, 2002, 2, 228-251.	0.8	19
157	More Medical Comorbidities in Patients With Bipolar Disorder From the United States Than From the Netherlands and Germany. Journal of Nervous and Mental Disease, 2014, 202, 265-270.	1.0	19
158	The relationship between self-reported borderline personality features and prospective illness course in bipolar disorder. International Journal of Bipolar Disorders, 2017, 5, 31.	2.2	19
159	Beyond evidenceâ€based treatment of bipolar disorder: Rational pragmatic approaches to management. Bipolar Disorders, 2019, 21, 650-659.	1.9	19
160	Neurobiology of bipolar illness: implications for future study and therapeutics. Annals of Clinical Psychiatry, 2003, 15, 85-94.	0.6	19
161	Cross-tolerance between carbamazepine and valproate on amygdala-kindled seizures. Epilepsy Research, 1993, 16, 37-44.	1.6	18
162	Use of single case analyses in offâ€onâ€offâ€on trials in affective illness: A demonstration of the efficacy of nimodipine. Depression, 1994, 2, 259-271.	0.6	18

#	Article	IF	CITATIONS
163	Early psychosocial stressors: relationship to suicidality and course of bipolar illness. Clinical Neuroscience Research, 2002, 2, 161-170.	0.8	18
164	Prevalence of axis <scp>II</scp> comorbidities in bipolar disorder: relationship to mood state. Bipolar Disorders, 2018, 20, 303-312.	1.9	18
165	Multigenerational transmission of liability to psychiatric illness in offspring of parents with bipolar disorder. Bipolar Disorders, 2018, 20, 432-440.	1.9	18
166	Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data. Journal of Affective Disorders, 2020, 272, 508-520.	4.1	18
167	Morbidity in treated bipolar disorder: A oneâ€year prospective study using daily life chart ratings. Depression, 1994, 2, 95-104.	0.6	17
168	CSF Thyrotropin-Releasing Hormone Gender Difference. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 349-353.	1.8	17
169	Predictors of psychosocial outcome of bipolar disorder: data from the Stanley Foundation Bipolar Network. International Journal of Bipolar Disorders, 2019, 7, 28.	2.2	17
170	Prophylaxis of Bipolar Affective Disorders. International Review of Psychiatry, 1990, 2, 277-320.	2.8	16
171	Nimodipine Increases CSF Somatostatin in Affectively III Patients. Neuropsychopharmacology, 1995, 13, 75-83.	5.4	16
172	Tolerance to the Prophylactic Effects of Carbamazepine and Related Mood Stabilizers in the Treatment of Bipolar Disorders. CNS Neuroscience and Therapeutics, 2011, 17, 649-660.	3.9	16
173	Does BDNF genotype influence creative output in bipolar I manic patients?. Journal of Affective Disorders, 2012, 139, 181-186.	4.1	16
174	Post-dexamethasone cortisol correlates with severity of depression before and during carbamazepine treatment in women but not men. Acta Psychiatrica Scandinavica, 2001, 104, 397-401.	4.5	16
175	Stress sensitization, kindling, and conditioning. Behavioral and Brain Sciences, 1985, 8, 372-373.	0.7	15
176	Effects of carbamazepine on serum electrolytes in affectively ill patients. Psychological Medicine, 1986, 16, 331-335.	4.5	15
177	Effect of carbamazepine on mean urinary free cortisol excretion in patients with major affective illness. Psychopharmacology, 1986, 88, 115-118.	3.1	15
178	More illness in offspring of bipolar patients from the U.S. compared to Europe. Journal of Affective Disorders, 2016, 191, 180-186.	4.1	15
179	Myriad of implications of acetyl- <scp>l</scp> -carnitine deficits in depression. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 8475-8477.	7.1	15
180	Double jeopardy in the United States: Early onset bipolar disorder and treatment delay. Psychiatry Research, 2020, 292, 113274.	3.3	15

#	Article	IF	CITATIONS
181	Further Evidence of a Cohort Effect in Bipolar Disorder. Journal of Clinical Psychiatry, 2016, 77, 1043-1049.	2.2	15
182	New findings from the bipolar collaborative network: Clinical implications for therapeutics. Current Psychiatry Reports, 2006, 8, 489-497.	4.5	14
183	Increases in multiple psychiatric disorders in parents and grandparents of patients with bipolar disorder from the USA compared with The Netherlands and Germany. Psychiatric Genetics, 2015, 25, 194-200.	1.1	14
184	Coadministration of gabapentin or MK-801 with lamotrigine slows tolerance to its anticonvulsant effects on kindled seizures. Pharmacology Biochemistry and Behavior, 2003, 74, 565-571.	2.9	13
185	Age at Onset of Bipolar Disorder Related to Parental and Grandparental Illness Burden. Journal of Clinical Psychiatry, 2016, 77, e1309-e1315.	2.2	13
186	Pyruvate Dehydrogenase Interactions with Peripheral-Type Benzodiazepine Receptors. Journal of Neurochemistry, 1989, 52, 110-116.	3.9	12
187	Parental attitudes towards early intervention in children at high risk for affective disorders. Journal of Affective Disorders, 2002, 70, 117-124.	4.1	12
188	The status of the sensitization/kindling hypothesis of bipolar disorder. Current Psychosis & Therapeutics Reports, 2004, 2, 135-141.	0.1	12
189	Heading off depressive illness evolution and progression to treatment resistance. Dialogues in Clinical Neuroscience, 2015, 17, 105-109.	3.7	11
190	Adding Increased Energy or Activity to Criterion (A) of the DSM-5 Definition of Hypomania and Mania. Journal of Clinical Psychiatry, 2019, 80, .	2.2	11
191	A double-blind, placebo-controlled trial of eicosapentanoic acid in rapid cycling bipolar disorder. Bipolar Disorders, 2002, 4, 26-27.	1.9	10
192	Childhood-Onset Bipolar Disorder: The Perfect Storm. Psychiatric Annals, 2009, 39, 879-886.	0.1	10
193	Contingent tolerance to carbamazepine is associated with lowering of amygdala-kindled seizure thresholds. Experimental Neurology, 1991, 114, 300-306.	4.1	9
194	Adjunctive strategies in the treatment of refractory bipolar depression: clinician options in the absence of a systematic database. Expert Opinion on Pharmacotherapy, 2005, 6, 531-546.	1.8	9
195	The Child Network for Parents to Track Their Child's Mood and Behavior. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 840-843.	1.3	9
196	Axis II Personality Disorders Are Linked to an Adverse Course of Bipolar Disorder. Journal of Nervous and Mental Disease, 2018, 206, 469-472.	1.0	9
197	The Kindling/Sensitization Model and Early Life Stress. Current Topics in Behavioral Neurosciences, 2020, 48, 255-275.	1.7	9
198	Relationship of clinical course of illness variables to medical comorbidities in 900 adult outpatients with bipolar disorder. Comprehensive Psychiatry, 2015, 56, 21-28.	3.1	8

#	Article	IF	CITATIONS
199	Debate: Fomenting controversy regarding pediatric bipolar disorder. Child and Adolescent Mental Health, 2019, 24, 95-96.	3.5	8
200	Relationship of comorbid personality disorders to prospective outcome in bipolar disorder. Journal of Affective Disorders, 2020, 276, 147-151.	4.1	8
201	25 Years of the International Bipolar Collaborative Network (BCN). International Journal of Bipolar Disorders, 2021, 9, 13.	2.2	8
202	How to prevent the malignant progression of bipolar disorder. Revista Brasileira De Psiquiatria, 2020, 42, 552-557.	1.7	8
203	Overlaps Between Schizophrenia and Bipolar Disorder. Psychiatric Annals, 2010, 40, 106-112.	0.1	8
204	Differential Effects of Acute and Repeated Electrically and Chemically Induced Seizures on [3H]Nimodipine and [¹²⁵ 1]Omegaâ€Conotoxin GVIA Binding in Rat Brain. Epilepsia, 1989, 30, 487-492.	5.1	7
205	Repetitive TMS as a Probe of Mood In Health and Disease. CNS Spectrums, 1997, 2, 39-44.	1.2	7
206	Prospective and retrospective life-charting in posttraumatic stress disorder (the PTSD-LCM): A pilot study. Journal of Traumatic Stress, 2001, 14, 229-239.	1.8	7
207	Prevention of recurrent affective episodes using extinction training in the reconsolidation window: A testable psychotherapeutic strategy. Psychiatry Research, 2017, 249, 327-336.	3.3	7
208	The Challenges of Children with Bipolar Disorder. Medicina (Lithuania), 2021, 57, 601.	2.0	7
209	A call for improving lithium literacy among clinicians and patients. International Journal of Bipolar Disorders, 2022, 10, 5.	2.2	7
210	Disturbing Lack of Early Intervention Studies in Bipolar Disorder. JAMA Psychiatry, 2018, 75, 1201.	11.0	6
211	A commentary on youth onset bipolar disorder. Bipolar Disorders, 2021, 23, 834-837.	1.9	6
212	Promising avenues of therapeutics for bipolar illness. Dialogues in Clinical Neuroscience, 2008, 10, 193-201.	3.7	6
213	Psychosocial Stressors as Predisposing Factors to Affective Illness and PTSD: Potential Neurobiological Mechanisms and Theoretical Implications. , 2003, , 491-525.		5
214	Myth of evidence-based medicine for bipolar disorder. Expert Review of Neurotherapeutics, 2009, 9, 1271-1273.	2.8	5
215	Decreased responsiveness following lithium discontinuation in bipolar disorder: A naturalistic observation study. Psychiatry Research, 2017, 247, 305-309.	3.3	5
216	Bipolar II Disorder: Not So Sure It Is Time for Something New. Canadian Journal of Psychiatry, 2019, 64, 070674371985209.	1.9	5

#	Article	IF	CITATIONS
217	Isn't the evidence base for pediatric bipolar disorder already sufficient to inform clinical practice?. Bipolar Disorders, 2020, 22, 664-665.	1.9	5
218	A Multisymptomatic Child With Bipolar Disorder. primary care companion for CNS disorders, The, 2017, 19, .	0.6	5
219	Complex Combination Therapy: The Evolution Toward Rational Polypharmacy in Lithium-Resistant Bipolar Illness. , 2006, , 135-167.		4
220	More assortative mating in US compared to European parents and spouses of patients with bipolar disorder: implications for psychiatric illness in the offspring. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 237-245.	3.2	4
221	The Sorry State of Treatment Research in Bipolar Disorder. Journal of Nervous and Mental Disease, 2012, 200, 924-927.	1.0	3
222	A shocking deficit in bipolar disorder treatment research funding. Bipolar Disorders, 2020, 22, 864-865.	1.9	3
223	The Epigenetic Connection to Black Disparity. Journal of Clinical Psychiatry, 2021, 82, .	2.2	3
224	Psychotrophic Mechanisms of Action of Antiepileptic Drugs in Mood Disorder. Medical Psychiatry, 2008, , 379-400.	0.2	3
225	Treatment of Bipolar Depression. , 2011, , 197-237.		3
226	Illness Progression as a Function of Independent and Accumulating Poor Prognosis Factors in Outpatients With Bipolar Disorder in the United States. primary care companion for CNS disorders, The, 2014, 16, .	0.6	3
227	Biased Public Health Perspective on Depression Treatment: Media Bias on Publication Bias. American Journal of Psychiatry, 2009, 166, 934-935.	7.2	2
228	Monitoring Children's Mood and Behavior. American Journal of Psychiatry, 2015, 172, 909-909.	7.2	2
229	Bipolar <scp>II</scp> : Comments on its validity and utility. Bipolar Disorders, 2018, 20, 280-281.	1.9	2
230	Number, Severity, and Quality of Symptoms Discriminate Early-Onset Bipolar Disorder from Attention-Deficit/Hyperactivity Disorder. Psychiatric Annals, 2014, 44, 416-422.	0.1	2
231	Controversies in the Psychopharmacology of Bipolar Disorder. Journal of Clinical Psychiatry, 2014, 75, e30-e30.	2.2	2
232	Management commentary. , 0, , 252-258.		1
233	Postâ€dexamethasone cortisol correlatesâ€`with severity of depression before andâ€`during carbamazepine treatment in women but not men. Acta Psychiatrica Scandinavica, 2001, 104, 397-401.	4.5	1
234	Illnesses in siblings of US patients with bipolar disorder relate to multigenerational family history and patients severity of illness. Journal of Affective Disorders, 2017, 207, 313-319.	4.1	1

#	Article	IF	CITATIONS
235	Alternative approaches to refractory depression in bipolar illness. Depression and Anxiety, 1997, 5, 175-189.	4.1	1
236	Mechanisms of Illness Progression in the Recurrent Affective Disorders. , 2012, , 31-46.		1
237	Nimodipine Increases CSF Somatostatin in Affectively Ill Patients. Neuropsychopharmacology, 1995, 13, 75-83.	5.4	1
238	Little Agreement on Treating Residual Bipolar Disorder Symptoms in a Child. primary care companion for CNS disorders, The, 2020, 22, .	0.6	1
239	The course of bipolar disorder in pregnant versus non-pregnant women. International Journal of Bipolar Disorders, 2021, 9, 35.	2.2	1
240	Are personality disorders in bipolar patients more frequent in the US than Europe?. European Neuropsychopharmacology, 2022, 58, 47-54.	0.7	1
241	Neonatal Developmental Neuroplasticity: A Critical Contribution from Environment. , 0, , 835-848.		0
242	Interview: Bipolar disorder treatment research: new initiatives needed. Neuropsychiatry, 2011, 1, 21-26.	0.4	0
243	Neglected treatment research in bipolar disorder: a congressional mandate would help. Expert Review of Neurotherapeutics, 2013, 13, 739-741.	2.8	0
244	Why the discrepancy between antidepressant drug use and evidence base in bipolar disorder?. Future Neurology, 2014, 9, 285-288.	0.5	0
245	Relative absence of studies in bipolar depression. International Clinical Psychopharmacology, 2015, 30, 239-240.	1.7	0
246	The kindling/sensitization model and the pathophysiology of bipolar disorder. , 0, , 204-218.		0
247	New perspectives on the course and treatment of bipolar disorder. Minerva Psychiatry, 2017, 58, .	0.3	0
248	Early Detection and Preventive Treatment in Bipolar Disorder. American Journal of Psychiatry, 2020, 177, 867-867.	7.2	0
249	Preliminary evaluation of the utility of parental ratings in a Child Network. Psychiatry Research, 2020, 290, 112908.	3.3	0
250	Mechanisms of Illness Progression in the Recurrent Affective Disorders. , 2013, , 35-50.		0
251	This issue: Differentiating Pediatric Bipolar Disorder from Attention-Deficit/Hyperactivity Disorder. Psychiatric Annals, 2014, 44, 406-408.	0.1	0